Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan nebivolol “approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Mylan's beta blocker nebivolol is "approvable" May 31 for treatment of hypertension. "Final approval of nebivolol is contingent upon successfully satisfying additional FDA requirements regarding certain aspects of the preclinical data and finalization of the labeling," Mylan said. The company is conducting a preclinical study, expected to be complete by year end, which it believes will answer FDA's questions. The agency extended nebivolol's initial user fee deadline of Feb. 28 by 90 days following the sponsor's submission of an "additional presentation of already submitted data" (1Pharmaceutical Approvals Monthly March 2005, p. 8). Mylan announced during a June 14 conference call that it is also targeting a congestive heart failure claim for nebivolol and expects to have a licensing partner by fall...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel